Abevmy Warnings

Gastrointestinal Perforations: Gastrointestinal perforation, some fatal, is reported in bevacizumab-treated patients. Bevacizumab must be discontinued in patients with gastrointestinal perforation (see Dosage & Administration and Precautions)
Surgery and Wound Healing Complications: Bevacizumab-treated patients have increased incidence of wound healing and surgical complications, including serious and fatal complications. Bevacizumab must be discontinued in patients with wound dehiscence. The appropriate interval between termination of bevacizumab and subsequent elective surgery required to reduce the risks of impaired wound healing/wound dehiscence is not known. Bevacizumab must be discontinued at least 28 days before elective surgery. Bevacizumab must not be initiated for at least 28 days after surgery and until the surgical wound is fully healed (see Dosage & Administration, Precautions and Adverse Reactions).
Haemorrhage: In patients receiving bevacizumab, severe or fatal haemorrhage, including haemoptysis, gastrointestinal bleeding, central nervous system (CNS) haemorrhage, epistaxis, and vaginal bleeding occur more frequently. Bevacizumab must not be administered to patients with serious haemorrhage or recent haemoptysis (see Dosage & Administration, Precautions and Adverse Reactions).